|
The Aesthetic Authority Has Arrived
|
The editors at Dermatology Times are proud to announce a new aesthetics brand for multi-specialty physicians. Guided by our esteemed Editorial Director, Randolph Waldman, M.D., we provide a fresh, intelligent perspective of practical insights on technology, techniques, best practices and practice management solutions in a forum committed to diversity, advancing the discipline of aesthetic medicine and providing optimal outcomes for patients.
|
 "The Aesthetic Authority has arrived. It is quite simply the first "true" multi-specialty aesthetic publication that is created by and designed for today's aesthetic practitioners. The goal is to provide useful information and tips and pearls that will help all of us in our practices."
|
|
|
|
Patient Insight: What They’re Reading
|
In this weekly report, we curate a list of consumer media articles on aesthetic topics to keep you up-to-date with what your patients are reading. This week’s includes post-surgical pain management, Emsculpt for pelvic floor weakness, Botox, men, hidradenitis suppurativa and alopecia.
|
Revance Therapeutics announces BLA acceptance for their long-acting neuromodulator, DaxibotulinumtoxinA (DAXI), with an action date set for November 25, 2020.
As nonsurgical aesthetic procedures continue to grow, so do the number of medical spas that perform cosmetic treatments. According to Dr. Renato Saltz, that’s not necessarily a bad thing.